REMS
Contraindicated in:
Pregnancy
;Use Cautiously in:
Women of reproductive potential
;Exercise Extreme Caution in:
CV: hypotension, chest pain, palpitations, tachycardia
Derm: rash, pruritus
F and E: hyperkalemia
GI: taste disturbances, abdominal pain, anorexia, constipation, diarrhea, nausea, vomiting
GU: proteinuria, renal impairment
Hemat: AGRANULOCYTOSIS, neutropenia
Neuro: dizziness, fatigue, headache, insomnia
Resp: cough
Misc: ANGIOEDEMA, fever
Drug-drug:
Drug-Natural Products:
Drug-Food:
Hypertension
Left Ventricular Dysfunction PostMyocardial Infarction
Diabetic Nephropathy
Renal Impairment
Absorption: 6075% absorbed following oral administration (↓ by food).
Distribution: Well distributed to tissues.
Half-Life: Infants with HF: 3.3 hr (range 1.212.4 hr); Children: 1.5 hr (range 0.982.3 hr); Adults: 1.9 hr (↑ to 2040 hr in renal impairment); Adults with HF: 2.1 hr.
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | 1560 min | 6090 min | 612 hr |
‡Full effects may not be noted for several wk.
May cause fetal harm. Advise women of reproductive potential to use effective contraception, notify health care provider immediately if pregnancy is planned or suspected, and avoid breastfeeding. Captopril should be discontinued as soon as possible when pregnancy is detected. Conduct serial ultrasound exams in pregnant patients exposed to captopril; may cause oligohydramnios. Monitor infants exposed to captopril in utero for hypotension, oliguria, and hyperkalemia. If oliguria or hypotension occurs, support BP and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.
NDC Code